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Main text 
Sir, 
Non-alcoholic fatty liver disease (NAFLD) is common in people living with HIV (PLWH) (1). A recent 
update to European guidance suggests screening for NAFLD in PLWH who also have metabolic 
syndrome (MetS) (2). Equivalent UK guidance does not yet exist. We therefore aimed to pilot a 
pragmatic approach to NAFLD, using data routinely collected in a UK HIV clinic setting. 
Consecutive adult PLWH attending for outpatient care were reviewed, and those with recurrently 
abnormal liver function (defined here as ALT >ULN on ≥2 occasions in last 13 months) were 
identified for further evaluation. At next planned visit we assessed central obesity (CO, by waist 
circumference (WC), per WHO cut-offs (3)) and insulin resistance (IR, defined as type 2 diabetes 
mellitus and/or elevated HbA1C >42mmol/mol). Where a presumptive diagnosis of NAFLD was made, 
staging was performed using the NAFLD Fibrosis Score (NAFLD-FS) (4).    
544 consecutive patients were evaluated. 100 (18%) had recurrently abnormal ALT. Of these 46 were 
excluded owing to viral hepatitis co-infection, alcohol excess, or other liver disease, and 10 did not 
attend for imaging. Of the remaining 44 patients (83% male, mean age 49.2 years, mean duration of 
diagnosed HIV infection 9.5 years, 91% ART treated), CO was present in 74%. By body mass index, 
  
25% were overweight (BMI 25-29.9) and 37% obese (BMI ≥30). Of note, 22% of subjects with CO had 
normal BMI. 23% had IR, and 14% MetS, all of whom had coexisting CO. 
After other causes were excluded, NAFLD was the commonest cause of liver disease, with a 
prevalence of 55% (representing 24% of all those with recurrently elevated ALT). A further 18% had 
possible NAFLD (CO/IR with no fat on USS). 88% of NAFLD cases were previously undiagnosed. 
Almost all patients with NAFLD had CO (sensitivity 94%, specificity 50%). BMI-defined obesity was 
less sensitive (Sn 80%, Sp 47%), and most did not have overt IR (Sn 29%, Sp 88%) or MetS. There was 
no association between presence of NAFLD and current or nadir CD4 count, duration of HIV 
infection, or duration or class of ART. Of subjects with NAFLD, 74% had low, 21% indeterminate, and 
5% high fibrosis risk.  
The prevalence of recurrently elevated ALT in a typical HIV cohort was high. NAFLD was the 
commonest cause of liver disease, and a large majority of cases were previously undiagnosed. As a 
pragmatic study based on current UK monitoring practice, we considered only those PLWH with 
elevated ALT. As such, we will have underestimated the true prevalence of NAFLD. WC will identify 
almost all PLWH with NAFLD, but the EACS approach of screening only those with MetS, whilst highly 
specific, appears to be insufficiently sensitive. It is noteworthy that, in the contemporary HIV clinic, 
‘lean NAFLD’ is uncommon.  
We therefore recommend implementation of routine WC measurement in UK clinical care (this will 
also enhance cardiovascular risk stratification), with targeting of NAFLD screening to those PLWH 
with CO. Future work should compare the Sn/Sp of this approach in the presence or absence of 
elevated ALT. 
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Insert 
Figure 1. Suggested approach to NAFLD in PLWH. CO, central obesity; IR, insulin resistance; MetS, 
metabolic syndrome; USS, ultrasound scan; NAFLD-FS, NAFLD fibrosis score; TE, transient 
elastography. Adapted from Dyson et al. (5) 
References 
1. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of 
nonalcoholic fatty liver disease in HIV-monoinfection. AIDS (London, England). 2017;31(11):1621-32. 
2. Society EAC. Guidelines 2017 [updated 01/10/2017. 9.0:[Available from: 
http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. 
3. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert 
consultation, Geneva, 8-11 December 2008. 2011. 
4. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis 
score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 
2007;45(4):846-54. 
5. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to 
diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211-8. 
 
  
 
